Intrexon Corp. Company Profile (NYSE:XON)

Analyst Ratings

Consensus Ratings for Intrexon Corp. (NYSE:XON) (?)
Ratings Breakdown: 3 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $52.63 (119.18% upside)

Analysts' Ratings History for Intrexon Corp. (NYSE:XON)
Show:
DateFirmActionRatingPrice TargetActions
7/17/2016JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/7/2016WunderlichReiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Stifel NicolausReiterated RatingBuy$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Griffin SecuritiesReiterated RatingBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016Bank of America Corp.Reiterated RatingNeutral$41.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016MizuhoReiterated RatingNeutral$28.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Merriman CapitalUpgradeNeutral -> Buy$85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015JPMorgan Chase & Co.DowngradeOverweight -> Neutral$45.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Intrexon Corp. (NYSE:XON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.20)($0.55)$46.26 million$43.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.18)($0.28)$41.82 million$41.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.21)($0.34)$40.84 million$53.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.04)$0.01$55.93 million$44.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.12)$0.25$32.90 million$33.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.16)$0.18$26.11 million$31.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q314($0.16)($0.53)$19.40 million$21.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.13)($0.11)$9.39 million$11.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q1$0.06$0.04$11.25 million$7.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2014Q413($0.14)($0.13)$8.38 million$7.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013($0.03)$0.15$9.79 million$6.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intrexon Corp. (NYSE:XON)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.22)($0.21)($0.22)
Q2 20162($0.22)($0.21)($0.22)
Q3 20162($0.33)($0.22)($0.28)
Q4 20162($0.28)($0.18)($0.23)
Q1 20171($0.04)($0.04)($0.04)
Q2 20171($0.08)($0.08)($0.08)
Q3 20171($0.19)($0.19)($0.19)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intrexon Corp. (NYSE:XON)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Intrexon Corp. (NYSE:XON)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/13/2016Randal J KirkCEOBuy41,830$23.92$1,000,573.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Randal J KirkCEOBuy124,475$29.85$3,715,578.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Randal J KirkCEOBuy237,525$30.69$7,289,642.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Suma KrishnanSVPSell20,900$35.66$745,294.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Randal J KirkCEOBuy555,556$27.00$15,000,012.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Donald LehrInsiderBuy1,850$15.99$29,581.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Randal KirkCEOBuy65,173$15.19$989,977.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Kelly HuangSVPBuy3,200$15.78$50,496.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Krish KrishnanCOOBuy20,900$14.21$296,989.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/27/2014Randal KirkCEOBuy243,001$25.72$6,249,985.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014Gregory Ian FrostSVPBuy100,000$25.95$2,595,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Jeffrey B KindlerDirectorBuy33,000$16.00$528,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Randal J KirkCEOBuy1,887,500$16.00$30,200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Thomas D ReedInsiderBuy1,800$16.00$28,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Thomas R KasserSVPBuy5,000$16.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Intrexon Corp. (NYSE:XON)
DateHeadline
07/23/16 09:01 AMAlkermes plc versus Intrexon Corporation Head to Head Compare - CML News
07/22/16 10:18 AMLmm LLC Increased Intrexon Corp (NYSE:XON) by $5.85 Million as Shares Rose - Consumer Eagle
07/21/16 10:13 AMIntrexon Corp Stock Price Increases Today - Press Telegraph
07/21/16 10:13 AMIntrexon Corporation (XON) Jumps 6.37% on July 20 - Equities.com
07/21/16 07:21 AMIntrexon's Genetically Engineered Mosquitoes (Finally) Have Data. What's Next? -
07/20/16 07:00 AMZIOPHARM Issues Statement Clarifying Speculation on Financing Activity - [GlobeNewswire] - BOSTON, July 20, 2016-- ZIOPHARM Oncology, Inc., due to recent developments, today issued the following statement clarifying market speculation regarding the Company’ s financing activity:. “The Company ...
07/19/16 07:34 PMIntrexon Corp (NYSE:XON)'s Company Shares Increased 6.26% After Low Volatility - Consumer Eagle
07/19/16 08:19 AMZiopharm investigating death in Ph I trial of brain cancer gene therapy
07/19/16 08:19 AMOragenics, Inc. Announces NYSE MKT Acceptance of its Plan of Compliance
07/19/16 08:00 AMOxitec and Piracicaba City Hall Start Downtown Release of Friendly™ Aedes - [PR Newswire] - Oxitec and Piracicaba City Hall today start the release of Friendly™ Aedes mosquitoes in downtown Piracicaba, Brazil. "The results obtained so far show that Friendly™ Aedes works and is able to control a serious public health issue that has been affecting the health of Brazilians for decades.
07/19/16 07:00 AMZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer - [GlobeNewswire] - BOSTON, July 19, 2016-- ZIOPHARM Oncology, Inc. today provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12+ orally administered veledimex in recurrent or progressive ...
07/18/16 03:34 PMIntrexon Corp. – Value Analysis (NYSE:XON) : July 18, 2016 -
07/18/16 04:37 AMHC Stocks in Top Row: Agilent Technologies Inc (NYSE:A) Intrexon Corp (NYSE:XON) - share market updates (press release)
07/17/16 04:49 AMLagoda Investment Management LP Increased Intrexon Corp (NYSE:XON) by $5.99 Million as Shares Rose - Consumer Eagle
07/16/16 10:33 AMCancer patient in Ziopharm drug trial dies after starting treatment
07/15/16 06:23 PMIntrexon Corporation (NYSE:XON) Current Analyst Ratings - Fiscal Standard
07/14/16 07:38 PMIntrexon Corporation Realized Volatility Hits Extreme Level - CML News
07/14/16 11:56 AMCORRECTED: Oxitec's genetically-engineered mosquitoes connected to 91% drop in Brazilian neighborhood's dengue fever cases -
07/14/16 11:00 AMBiotech news that matter for investors: Intrexon Corporation (NYSE:XON), Anavex Life Sciences Corp. (NASDAQ:AVXL) - The Voice Registrar
07/14/16 11:00 AMThird Security LLC Increased Intrexon Corp (NYSE:XON) by $3.27 Million as Shares Rose - Consumer Eagle
07/14/16 11:00 AMTime to Buy Intrexon Corp After Today's Huge Decline? - Consumer Eagle
07/14/16 08:00 AMDengue Fever Cases Drop 91% in Neighbourhood of Piracicaba, Brazil, Where Oxitec's Friendly™ Aedes Were Released - [PR Newswire] - Piracicaba's Epidemiologic Surveillance service released new data this week which showed a 91% reduction of dengue fever cases registered in the CECAP/Eldorado district, an area of 5,000 residents, in the 2015/2016 dengue-year as compared to the 2014/2015 period. The incidence decreased to just 12 cases in 2015/2016, the first year in which Friendly™ Aedes, the genetically engineered mosquitoes that fight wild Aedes aegypti, were released there, versus 133 cases in the previous year. According to Epidemiologic Surveillance the rest of the municipality saw a 52% reduction in dengue fever incidence during the same period, from 3,487 cases in the 2014/2015 period to 1,676 cases in 2015/2016.
07/13/16 10:12 AMZiopharm Oncology (ZIOP) Plans CD33 CAR-T Cell Therapy Phase 1 Targeting AML
07/12/16 07:36 PMInsider Trading Roundup: Intrexon Corp (NYSE:XON) - The Voice Registrar
07/12/16 09:40 AMBRIEF-Ziopharm plans for Phase I clinical trial with CD33 CAR-T cell therapy targeting acute myeloid leukemia
07/11/16 07:12 PMCompany Shares of Intrexon Corporation (NYSE:XON) Rally 1.33% - TheFounders Daily
07/11/16 10:36 AMHere's Why Ziopharm Oncology, Inc. Shares Took a Pounding and Lost 30% in June -
07/11/16 07:46 AMIntrexon Corp. breached its 50 day moving average in a Bullish Manner : XON-US : July 11, 2016 -
07/11/16 04:32 AMStock Performance Rundown on: Intrexon Corporation (NYSE:XON) - Press Telegraph
07/09/16 06:32 PMAre Analysts Bearish Intrexon Corp (NYSE:XON) After Last Week? - Press Telegraph
07/08/16 10:11 AMIntrexon : Oxitec Named Social Impact Investment of the Year
07/07/16 10:03 AMThis Analyst Just Tripled Intrexon's Zika Drug Sales Estimates
07/07/16 04:00 AMOxitec Named Social Impact Investment of the Year - [PR Newswire] - Oxitec is delighted to have been named Social Impact Investment of the Year at the UK Business Angels Association (UKBAA) Angel Investment Awards 2016. Hadyn Parry, Chief Executive Officer of Oxitec, said, "It is an honour to have received this award from the UK Business Angels Association. Oxitec has benefitted greatly from investor support since our spinout from the University of Oxford in 2002.
07/06/16 04:11 PMIntrexon Just Diluted Ziopharm Investors Big Time -
07/06/16 04:34 AMIntrexon Corporation (XON) Jumps 7.15% on July 04 - Equities.com
07/05/16 06:57 PMInvestor News: Deadline in Lawsuit against Intrexon Corp (NYSE:XON) on July 5, 2016 upcoming - GroundReport
07/03/16 04:37 AMIntrexon Corporation (NYSE:XON) Sellers Increased By 5.6% Their Shorts - Press Telegraph
07/02/16 09:53 AMLmm LLC Increased Intrexon Corp (NYSE:XON) by $5.85 Million as Shares Rose - Press Telegraph
07/02/16 09:53 AMIntrexon Corporation (XON) Jumps 6.8% on June 29 - Equities.com
07/02/16 09:53 AMLagoda Investment Management LP Increased Intrexon Corp (NYSE:XON) by $5.99 Million as Shares Rose - Press Telegraph
07/01/16 09:07 PMINTREXON 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Intrexon Corporation – XON - [GlobeNewswire] - NEW ORLEANS, July 01, 2016-- Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only ...
07/01/16 05:25 PM4-Day Deadline Alert: Lundin Law PC Announces Securities Class Action Lawsuit Against Intrexon Corporation And Reminds Shareholders With Losses In Excess of $50,000 To Contact The Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / July 1, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Intrexon Corporation ("Intrexon" or the "Company") (NYSE: XON ) concerning ...
07/01/16 04:26 PMINTREXON CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement -
07/01/16 10:03 AMINTREXON CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
06/30/16 07:35 PMIn Brief Former NCI Director Broder to Retire from Intrexon - The Cancer Letter Publications
06/30/16 03:28 PMINTREXON CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
06/30/16 03:01 PMIntrexon Appoints Fred Hassan, Distinguished Life Sciences Executive, to Board of Directors - [PR Newswire] - GERMANTOWN, Md., June 30, 2016 /PRNewswire/ -- Intrexon Corporation (XON), a leader in synthetic biology, today announced the appointment of Fred Hassan to its Board of Directors, effective June 30. Mr. Hassan is currently a Partner and Managing Director at Warburg Pincus LLC, a global private equity firm. Mr. Hassan has also been a director of Time Warner Inc. since October 2009 and director of Amgen, Inc. since July 2015. In the course of his career, he has held numerous directorships, including those at Avon Products, Inc. from 1999 to 2013, Bausch & Lomb from 2010 until its acquisition by Valeant Pharmaceuticals International, Inc. in 2013, and Valeant Pharmaceuticals International, Inc. from 2013 to 2014. Mr. Hassan has chaired notable pharmaceutical industry organizations including The Pharmaceutical Research and Manufacturers of America (PhRMA) and The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) and is also a member of The Business Council. He received B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School.
06/30/16 11:52 AMGPM Reminds Investors of the July 5 Deadline in the Class Action Lawsuit Against Intrexon Corporation - [Business Wire] - Glancy Prongay & Murray LLP reminds investors of the July 5, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class of investors who purchased Intrexon Corporation securities between May 12, 2015 and April 20, 2016, inclusive .
06/30/16 10:01 AMIntrexon Corp on Focus After Raising In Today's Session - Engelwood Daily
06/30/16 09:40 AMZiopharm Co-Dependency Spirals Down in Amended Intrexon Deal -

Social

About Intrexon Corp.

Intrexon Corp. logoIntrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: XON
  • CUSIP:
Key Metrics:
  • Previous Close: $24.33
  • 50 Day Moving Average: $25.38
  • 200 Day Moving Average: $29.63
  • P/E Ratio: N/A
  • P/E Growth: 0.27
  • Market Cap: $2.84B
  • Beta: 1.57
  • Current Year EPS Consensus Estimate: $-1.25 EPS
  • Next Year EPS Consensus Estimate: $-0.7 EPS
Additional Links:
Intrexon Corp. (NYSE:XON) Chart for Sunday, July, 24, 2016